Who can independently scrutinise my decision?
UHNW Aesthetics provides the institutional pathway; an individual medical review requires a separate Phase 2 physician mandate.
Within an accepted Phase 2 mandate, the reviewing physician may assess the proposed treatment, chosen practitioner, team, infrastructure, evidence gaps, identifiable risks and long-term strategy.
UHNW remains outside medical judgement and treatment. The treating physician remains responsible, and physician and clinic choice remain free.
You decide on the basis of examined substance—not public perception.What role does UHNW Aesthetics have in our mandate?
UHNW Aesthetics provides the institutional pathway; a directly mandated physician owns any individual medical review.
Within documented authority, the Family Office may coordinate timing, documents and communications. It neither makes medical judgements nor replaces the Principal’s consent.
Under an accepted Phase 2 mandate, the reviewing physician may organise relevant statements, evidence gaps and unresolved conditions within a traceable decision framework.
The Family Office coordinates within authority; the physician owns the medical review.What specialist capability does UHNW Aesthetics add?
Your agency retains the client relationship; any medical review belongs to a directly mandated physician.
Within an accepted Phase 2 mandate, the reviewing physician may examine the contemplated proposal, specialist evidence, team and facility capability, emergency arrangements, aftercare and revision planning.
Your agency remains within documented authority. UHNW handles institutional access and permitted non-medical coordination only.
Your agency retains the relationship; medical judgement remains physician-owned.What will I learn beyond reputation and recommendations?
You gain the specialist perspective behind ratings, recommendations, television appearances and social-media visibility.
These signals describe recognition and public perception. They show only to a limited extent whether a treatment is appropriate in your particular case and whether the practitioner, team and facility possess the necessary specialist and organisational depth.
Within an accepted Phase 2 mandate, the reviewing physician examines specialisation, outcome evidence, team stability, risk management, emergency capability, revision expertise and long-term responsibility. You retain the decision.
You do not delegate your decision to reputation—you have its substance examined.What value does this add to our decision process?
A reputation-led selection becomes a traceable decision framework in aesthetic medicine.
The review separates documented competence from public perception, identifies information gaps and shows what must be resolved before approval is given: the medical rationale, the practitioner's personal responsibility, the team, the facility, aftercare and revision planning.
This structure supports internal assessment and communication with the principal. Risks become visible at an early stage, escalation points are placed in a clear order and opinions from outside the relevant discipline are supplemented by professor-led review.
The office receives an auditable decision process rather than another recommendation.How does the review strengthen our client service?
Your knowledge of the market and the client is extended by an independent medical review layer.
UHNW Aesthetics examines whether your selection is sound not only organisationally and reputationally, but also medically: the suitability of the proposed treatment, the practitioner's specialisation, team quality, the resilience of the facility and the management of complications and long-term consequences.
You can therefore offer the client more than access and coordination. You bring specialist guidance to the process—guidance that recognises marketing as marketing and asks the questions that routinely remain unanswered outside the relevant medical discipline.
International client service gains substance through specialist review within the relevant discipline.Which elements of my proposed treatment are examined?
Under a direct physician mandate, the review may extend from the indication to the care system’s long-term capacity for revision.
It examines your starting position, the plausibility of the proposed procedure, alternatives and limits, together with the selected practitioner's specific specialisation, aesthetic judgement and case-specific competence.
The team, operating and emergency environment, documentation, aftercare, complication management and future revisions are equally important. Procedure numbers are only one data point; the decision becomes robust only when all levels are considered together.
The decision is examined as a system—not as an isolated procedure.Which risks across the care pathway are examined?
Under a direct physician mandate, the entire chain of responsibility may be examined, from the indication to long-term aftercare.
This includes the medical rationale, the practitioner's specific competence for the case, team stability and the technical and organisational capability of the facility. Particular attention is paid to the points of handover between those involved.
Who is available outside the operating theatre? How are complications recognised and escalated? Who is responsible for aftercare, emergency care and revision—particularly when treatment takes place abroad? The result is a systemic risk review for the engagement.
A robust engagement requires a robust chain of responsibility.How deeply is an existing proposal examined?
An existing proposal may be examined under a direct physician mandate for its indication, supporting evidence and operational resilience.
The freely chosen, directly mandated physician assesses whether the proposed treatment addresses the specific question, which specialisation and comparable experience are documented, and how much weight the qualifications presented carry.
It then considers the team, facility, operating conditions, emergency arrangements, documentation, aftercare, complication management and revision capability. Rather than a new provider list, you receive a precise assessment of your selection: its robust elements, unresolved questions and the evidence that should be requested.
We do not replace your selection—we make its resilience visible.What can I access before an individual review?
After successful validation, the knowledge area approved for your topic may be opened once protected access is operationally activated.
There you learn which medical and organisational factors matter for the particular aesthetic procedure. The material identifies typical areas of risk, relevant indicators of qualification, frequently overlooked dependencies and the questions that should be answered before a decision is made.
You can assess a practitioner's statements more precisely and consider the quality of a proposal beyond its public presentation. If the need for an individual review becomes apparent, the next pathway is clearly defined.
Protected knowledge turns uncertainty into a precise question.How can our team use the protected knowledge?
Your staff receive indication-specific review criteria for preparation, documentation and decision-making.
The protected knowledge sets out typical risk scenarios, specific questions and the evidence that carries genuine weight when assessing the practitioner, team and facility. Public statements can therefore be distinguished from professionally reliable information.
A qualified Phase 1 framework is available before any individual case review. The office can identify what may be resolved within that framework and when only a new direct mandate between the Principal and a freely chosen, legally licensed physician may open a confidential Phase 2 review.
For the family office, knowledge becomes an operational review tool.How does general knowledge become case-specific guidance?
You receive not a general library, but a defined knowledge area for the specific field of treatment.
The material can be integrated directly into your preparation: required records, relevant qualifications, questions concerning the team and facility, emergency provision, aftercare and long-term strategy.
When an enquiry goes beyond the general guidance, Phase 1 ends. An individual review framework arises only under a new direct mandate with the freely chosen physician; sensitive case data remain exclusively in that physician’s professional system.
Specialist knowledge becomes specific preparation for your client.Could the review lead to a treatment offer?
Within UHNW Aesthetics, professor-led expertise explains only the general Phase 1 criteria; it does not assess your personal medical decision.
The institution does not turn Phase 1 into a treatment offer or placement with a particular provider. This structural boundary also applies if you expressly request a clinical service.
Personal medical assessment belongs exclusively to the freely chosen, directly mandated Phase 2 physician within that physician’s professional system. UHNW receives neither the case file nor the medical fee.
Professor-led authority explains Phase 1; the directly mandated physician is responsible for Phase 2.How do we verify independence from provider interests?
The Phase 1 role and any subsequent direct physician mandate are documented separately and screened for conflicts of interest.
Within Phase 1, authors receive only general module questions, not a medical case file. Their role, specialist suitability and any links with the practitioner or facility are reviewed before they become involved.
An individual medical question is entrusted only to the physician freely chosen and directly mandated by the Principal. The family office coordinates solely within documented authority; UHNW neither holds the case file nor conducts the medical Phase 2 review.
The role of every expert is defined before that expert becomes involved.Does our client relationship remain protected?
Your agency continues to lead the client relationship, communication and organisational support.
UHNW Aesthetics provides the institutional Phase 1 pathway and permitted non-medical coordination. Any individual Phase 2 assessment belongs to the directly mandated reviewing physician.
No parallel referral channel is created, no medical or referral fee is received and no financial interest is held in the reviewed provider. Your agency remains within its documented authority.
Your agency retains the relationship; the physician retains responsibility for medical review.What if my concern exceeds the published guidance?
A complex concern begins with a defined strategic process—not an impromptu remote opinion.
Before any expert becomes involved, the subject of review, the information required, the relevant disciplines and the sequence of the next stages are defined. Your identity is kept separate from the medical question.
Appropriately qualified specialists receive only the information required for their defined task, exclusively within the directly mandated physician’s professional system. Their identity, role and information scope are disclosed in advance.
Complexity produces more structure—not more participants without a defined task.How do we initiate a professor-led case review?
Individual case review begins with a confidential review plan in the directly mandated physician’s professional system.
That physician defines the medical question, required records, relevant disciplines and sequence of review stages. UHNW access data and the physician’s Phase 2 case file remain in separate systems.
The Principal authorises disclosure of personal data. The directly mandated physician maintains the case file and determines which information is professionally necessary to share; the office coordinates only within its documented authority. Tasks, information scope and confidentiality arrangements are specified before the relevant specialist becomes involved.
The Principal retains decision and authorisation rights; the physician is responsible for the medical case file.When are additional specialists involved?
Additional specialists are involved only for a specifically defined, unresolved specialist question.
Within its documented authority, your agency receives an administrative overview of the unresolved question, required expertise and communication route to the client. Medical records remain in the directly mandated physician’s system.
Only that physician decides whether additional appropriately authorised specialists are needed and which purpose-limited information they receive. The reason, participants and process are disclosed in advance to the Principal or their authorised representative.
Every additional specialist authority has a defined remit and a defined information boundary.Why is exceptional private access personally assessed?
Direct private access begins with a limited, non-medical preliminary review.
The preliminary review records only role, authority, topic, decision stage, region and a secure return channel. It is not a medical assessment and does not determine suitability for consultation or treatment.
Protected Phase 1 access requires operational activation, an approved access review and server-side authorisation. Any Phase 2 review is a separate direct physician mandate.
Direct private access is an exceptional decision made individually.Must we disclose our principal's identity?
For the preliminary professional access review, the focus is your family office—not the identity of the principal.
The review concerns the organisation, the applicant's role and the authority to represent the defined UHNW constituency. Client names, financial information and medical details do not form part of this stage.
Your office establishes access through its own authority. If Phase 2 is accepted, the directly mandated physician determines and securely requests the necessary medical information.
Institutional credentials open the route without disclosing the principal.What is required for our initial credentials review?
Your agency establishes eligibility through its own institutional standing and professional activity.
The required information is limited to organisation, role, authority, topic, decision stage, region and a secure return channel.
The names of represented clients, financial information and medical case data are not required at this stage. Protected access remains subject to operational activation and server-side authorisation.
The agency is reviewed. Its clients remain outside the preliminary access review.Who learns my identity during specialist review?
Your UHNW access validation and the physician’s Phase 2 case file remain in separate systems.
Medical Phase 2 data are not held in UHNW systems. Within the mandate, the directly appointed physician determines which purpose-limited information each participating specialist needs.
The Principal authorises disclosure of personal data. Participants, their roles and the scope of information are identified before each specialist disclosure.
Your identity remains separate from the specialist question submitted for professor-led review.How is our principal protected across disciplines?
UHNW access data and the medical Phase 2 case file remain in separate systems.
The directly mandated physician determines the information required for each discipline. A specialist receives only the purpose-limited extract needed for the defined task.
The Principal authorises data disclosure; the physician maintains the case file. A family office receives or coordinates information only within documented, purpose-specific authority to represent the Principal and access the relevant material.
The Principal’s authorisation and the physician’s responsibility for the case file remain distinct.How do we control the flow of client information?
Before any specialist is involved at the physician’s direction, your agency receives an overview of participants and information scope within its documented authority.
The directly mandated physician specifies the professional role, precise question, required records and intended access level. Case records remain in that physician’s professional system and are limited to the relevant review purpose.
The agency coordinates communication only within documented authority. Medical decisions, data authorisations and specialist disclosures remain the responsibility of the Principal and physician in their respective roles.
No specialist receives more information than the defined review task requires.Who is accountable for the review?
UHNW Aesthetics is a non-profit institution for general Phase 1 review under the medical leadership of Prof. Dr. med. A. Altintas, M.Sc.
The medical lead is a specialist in plastic and aesthetic surgery and is responsible within the institution only for the general Phase 1 review architecture, author governance and separation of roles. This position involves neither clinical treatment nor individual case assessment.
Medical Phase 2 case review is the exclusive responsibility of the legally licensed physician freely chosen and directly mandated by the Principal. Within that physician’s own system, they determine the scope and whether further specialist involvement is professionally necessary.
Responsibility is personally identified and professionally verifiable.What must be verifiable before engagement?
For Phase 1, your office has a clearly identified institution, personally accountable medical leadership and defined limits of service.
Before a Phase 1 engagement, the organisational form, titles, professional qualifications, author roles and institutional responsibilities must be verifiable. Individual medical review and treatment are outside that mandate.
In any subsequent Phase 2, the freely chosen physician becomes the Principal’s direct contracting party and is solely responsible for the case assessment, medical data and medical fee. The office acts only within documented authority.
The family office can attribute responsibility, role and specialist standard unambiguously.Which medical authority can we identify?
For Phase 1, you can identify personally accountable medical leadership and a general specialist framework under professorial responsibility.
Prof. Dr. med. A. Altintas, M.Sc., a specialist in plastic and aesthetic surgery, is responsible for the general Phase 1 review architecture and institutional separation of roles. UHNW does not conduct patient-specific case reviews.
For Phase 2, the Principal freely chooses and directly appoints a legally licensed physician. That physician is responsible for specialist review, any additional specialists, medical data and the medical fee, separately from UHNW and treatment.
Your agency can identify a specific professional authority—not an anonymous advisory structure.Can the review support planned treatment abroad?
Cross-border Phase 2 work is possible only after jurisdiction, licensure, conflicts, capacity and operational readiness have been reviewed.
The review considers not only the doctor and clinic, but also records, international availability, aftercare, emergency access, revision capability and the transfer of responsibility between the parties involved.
Before treatment, these elements are brought together in a professionally coordinated decision and safety framework. Local clinical care remains with the treating system; its resilience forms part of the review. Delivery of a Phase 2 mandate remains subject to the directly appointed physician’s professional, licensing and local legal requirements.
The place of treatment may change—the review methodology remains consistent.How is a cross-border engagement kept manageable?
An international engagement begins with a clear map of responsibility.
It identifies who makes medical decisions, which records must remain available across borders and who is responsible for complications, aftercare or revision.
Under the direct physician mandate, specialist questions, regional responsibilities, documentation requirements and escalation routes may be integrated into a review plan. The office coordinates only within its authority; delivery remains subject to jurisdiction, licensure, conflicts, capacity and operational approval.
Cross-border support requires defined handovers rather than geographical promises.What does international availability mean in practice?
Cross-border work combines a consistent review method with clearly defined local responsibility; it is not a blanket promise of availability.
Under the direct Phase 2 physician mandate, records, local care, aftercare and escalation routes are assessed for the relevant treatment jurisdiction. Only that physician decides whether further specialist involvement is professionally necessary.
This allows you to support the client consistently across borders without overlooking local circumstances, legal limits or the actual availability of care providers. Delivery of a Phase 2 mandate remains subject to the directly appointed physician’s professional, licensing and local legal requirements.
International engagements follow one review methodology with clear local responsibility.What supports exceptional direct private access?
Exceptional direct private access is preferably introduced through a family office, appointed agency or authorised representative. Only where that route is unavailable does the protected review of identity, access eligibility and fit begin.
Where no professional introduction is available, fit with the defined UHNW constituency is assessed exclusively within the protected process using substantive and verifiable eligibility evidence. The relevant evidence is specified only after a positive initial review; the open intake requests neither status examples nor supporting material. No single item produces automatic clearance.
Payment-card and credit-card programmes carry no evidential weight in the access review. Following a positive initial review, the supporting evidence required through the protected route is agreed with you directly.
Exceptional direct private access depends on verifiable eligibility and an individual access decision.How do we establish eligibility without naming the principal?
Your family office establishes eligibility through its organisation, role and professional authority to act.
The review concerns your institutional standing and authority to represent the relevant UHNW client segment. The principal's name, financial circumstances and medical records are not requested at first contact.
Digital submission of credentials is followed by personal assessment by the responsible access team. If access is approved, the professional route is opened and a named contact is assigned for the next stage.
The standing of the family office is sufficient for preliminary review—the principal remains protected.What must a first-time agency establish?
New agencies are assessed on the basis of their own professional standing.
The relevant criteria are verifiable organisational identity, activity within the relevant international client segment, the applicant's role and authority to act. Names or personal records of represented clients are not required for this stage.
Established partners use the existing protected route. New agencies submit their credentials through the preliminary access review and are then assessed personally by the responsible access team.
Professional credentials open the agency route—not disclosure of a client.What happens once my access is approved?
After approval and operational activation, the protected knowledge area relevant to your topic may be opened.
By appointment, a personal contact guides you through the relevant material online or in person, explains the next stage and identifies which questions can already be answered from the available knowledge.
If your concern requires an individual review, Phase 1 ends. A medical review plan is then established only under a new direct mandate with the physician you freely choose; UHNW receives no Phase 2 case data.
Access approval connects protected knowledge with a personally guided next step.How does our work begin once access is approved?
After approval and operational activation, your family office may receive the relevant protected knowledge and a structured personal introduction.
Your staff learn how to use the material, which records should be prepared for a particular concern and when an individual review is indicated. The principal's identity is not disclosed through general access.
An individual case begins only under a new direct mandate between the Principal and the freely chosen physician. Within their own professional system, that physician defines the question, information scope, disciplines and decision stages; the office coordinates only within documented authority.
Your office receives immediately usable knowledge and a defined route into individual case review.What do we receive after our credentials are approved?
After approval and operational activation, your agency may access a protected knowledge and working environment with personal guidance.
A named contact explains how the material can be used for different questions in aesthetic medicine and how specific client cases should be prepared. This provides specialist guidance before personal or medical details enter the process.
For complex concerns, the UHNW Phase 1 pathway ends. A separate medical review mandate is formed exclusively between the Principal and the freely chosen physician, who is responsible for strategy, confidentiality, information scope and any additional specialists required.
Your agency gains access to specialist knowledge without disclosing its client relationship.
